Literature DB >> 9248666

Competition of adenine nucleotides for a 1,3-[3H]-dipropyl-8-cyclopentylxanthine binding site in rat vas deferens.

A D Smith1, D J Cheek, I L Buxton, D P Westfall.   

Abstract

1. The binding of 1,3-[3H]-dipropyl-8-cyclopentylxanthine ([3H]-DPCPX), a specific adenosine A1 receptor antagonist, was examined in rat vas deferens membrane preparations using radioligand binding techniques. 2. 1,3-[3H]-Dipropyl-8-cyclopentylxanthine bound to these preparations with a KD of 1.07 +/- 0.14 nmol/L (n = 6). The density of [3H]-DPCPX binding sites was 133.38 +/- 5.57 fmol/mg protein. 3. Computer analysis indicated that nucleosides competed for [3H]-DPCPX binding at two distinct sites. The rank order of potency at the higher affinity site corresponded to R-phenylisopropyladenosine (R-PIA) > or = 2-chloroadenosine (2-CIADO) > or = cyclopentyladenosine (CPA) > or = N-ethylcarboxamidoadenosine (NECA) > s-phenylisopropyladenosine (s-PIA). Ki values were in the low nmol/L range. The rank order of nucleoside potency at the lower affinity site corresponded to R-PIA > or = CPA > or = NECA > or = 2-CIADO > S-PIA. Ki values were in the low mumol/L range. 4. Nucleotides competed for [3H]-DPCPX binding at a single site only. The rank order of potency at this site corresponded to alpha, beta-methylene ATP > or = beta, gamma-methylene ATP > or = ATP. Ki values were in the high mumol/L range. The site seemed to correspond with one of the two binding sites predicted by nucleoside competition binding. 5. The ATP-regenerating compound myokinase did not significantly change the competition curve for ATP, indicating that the competition for [3H]-DPCPX binding observed in the presence of ATP was due to an effect of ATP per se and not to an action of a degradation product. 6. The results demonstrate that in rat vasa deferentia there exist two distinct binding sites for [3H]-DPCPX. One of these sites binds only nucleosides and may represent an adenosine A1 receptor, as usually defined. The other site binds both nucleosides and nucleotides and may represent an atypical adenosine A1 receptor, an atypical P2 or a P3 purinoceptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9248666     DOI: 10.1111/j.1440-1681.1997.tb01233.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

Review 1.  Purinergic-receptor oligomerization: implications for neural functions in the central nervous system.

Authors:  Hiruyasu Nakata; Kazuaki Yoshioka; Toshio Kamiya
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 2.  Functions of heteromeric association between adenosine and P2Y receptors.

Authors:  Hiroyasu Nakata; Kazuaki Yoshioka; Toshio Kamiya; Hirofumi Tsuga; Koshi Oyanagi
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Regulation of cyclic AMP by extracellular ATP in cultured brain capillary endothelial cells.

Authors:  Z Anwar; J L Albert; S E Gubby; J P Boyle; J A Roberts; T E Webb; M R Boarder
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

4.  A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptor-mediated contractility in human cultured prostatic stromal cells.

Authors:  A Preston; M Frydenberg; J M Haynes
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

5.  Endogenous expression of adenosine A1, A2 and A3 receptors in rat C6 glioma cells.

Authors:  Carlos Alberto Castillo; José Luís Albasanz; Mercedes Fernández; Mairena Martín
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.